Raymond James Financial Inc. Takes Position in Certara, Inc. (NASDAQ:CERT)

Raymond James Financial Inc. purchased a new stake in Certara, Inc. (NASDAQ:CERT) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 340,649 shares of the company’s stock, valued at approximately $3,628,000. Raymond James Financial Inc. owned about 0.21% of Certara as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Blue Trust Inc. raised its stake in shares of Certara by 20.9% in the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock worth $56,000 after acquiring an additional 822 shares during the last quarter. Venturi Wealth Management LLC grew its stake in shares of Certara by 839.1% during the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock valued at $30,000 after purchasing an additional 2,509 shares during the last quarter. KBC Group NV increased its holdings in shares of Certara by 64.1% in the fourth quarter. KBC Group NV now owns 7,998 shares of the company’s stock valued at $85,000 after purchasing an additional 3,125 shares in the last quarter. Jane Street Group LLC raised its position in Certara by 2.6% in the 3rd quarter. Jane Street Group LLC now owns 147,393 shares of the company’s stock worth $1,726,000 after purchasing an additional 3,732 shares during the last quarter. Finally, GAMMA Investing LLC lifted its holdings in Certara by 442.2% during the 4th quarter. GAMMA Investing LLC now owns 8,421 shares of the company’s stock worth $90,000 after buying an additional 6,868 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on CERT shares. TD Cowen started coverage on Certara in a research note on Thursday, February 27th. They set a “buy” rating and a $16.00 price target on the stock. William Blair restated a “market perform” rating on shares of Certara in a research report on Thursday, February 27th. Barclays raised their price target on Certara from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research report on Friday, February 28th. Finally, Stephens reiterated an “overweight” rating and issued a $17.00 price objective on shares of Certara in a research report on Thursday, February 27th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Certara currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.83.

Certara Stock Performance

Shares of NASDAQ CERT opened at $10.12 on Friday. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $1.63 billion, a P/E ratio of -50.60, a P/E/G ratio of 9.29 and a beta of 1.60. Certara, Inc. has a 12 month low of $9.41 and a 12 month high of $19.18. The stock has a 50 day moving average of $12.47 and a 200-day moving average of $11.46.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.